The rationale behind endocrine therapy for breast cancer is the knowledge that certain tumours require oestrogen for their continued growth. Sources of oestrogen differ according to menopausal status; ovarian production predominates in premenopausal women whereas synthesis in peripheral tissues such as fat, muscle and the tumour itself is more important in post-menopausal patients (Miller, 1990) . The use of drugs specifically designed to block oestrogen biosynthesis irrespective of site of production is therefore an attractive strategy. Oestrogens lie at the end of a multistep pathway. Blockade can be achieved by inhibiting any of the individual transformations but more specific suppression is achieved by inhibiting the final step, which is unique to oestrogen biosynthesis. This reaction converts androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the trivial name for the enzyme of 'aromatase'). Consequently, enormous efforts have been expended in the development of aromatase inhibitors by synthesising either substrate analogues or drugs that interfere with the enzyme's prosthetic cytochrome p450 group. It has been known for some time that drug-induced inhibition of the aromatase enzyme may produce therapeutic benefits in patients with breast cancer. Agents such as aminoglutethimide were used without initially realising that they had anti-aromatase properties. Nevertheless, the major benefits of aminoglutethimide (which include a 33% objective response rate in unselected post-menopausal patients with advanced breast cancer) are probably achieved through inhibition of the aromatase system (Miller, 1989) . However, aminoglutethimide is not a potent aromatase inhibitor; it also lacks specificity and side-effects may be produced that are unrelated to oestrogen deprivation. Considerable resources have been invested in the development of second-and thirdgeneration drugs (Combs et al., 1995) . Results of studies on these aromatase inhibitors are now being published, as is reflected by the current issue of the Br. J. Cancer, which contains two such articles (Yates et al., 1996 and Bonnefoi et al., 1996) . It is thus opportune to review the current status of these drugs in terms of (i) anti-aromatase and endocrinological effects, (ii) clinical tolerability and efficacy, (iii) relationship with established endocrine treatments, (iv) future applications and (v) theoretical and practical perspectives. (Demers, 1994; Lipton et al., 1995) , and vorozole (Johnston et al., 1994; Goss et al., 1995) . Of the new non-steroidal aromatase inhibitors, fadrozole seems less effective in both inhibiting aromatase and suppressing circulating oestrogens (Demers, 1994) . Doubts have also been expressed about its specificity; changes in aldosterone secretion have been reported (Demers et al., 1993) , but at doses that produce maximal suppression of oestrogen, effects on aldosterone may not be of clinical significance .
Clinical tolerability and efficacy
These new aromatase inhibitors are administered orally (the exception is formestane, which requires intramuscular injection) and appear to be remarkably well tolerated, with no greater incidence of side-effects than might be expected from a placebo or from oestrogen suppression. However, it should be noted that the duration of treatment in most patients is still extremely limited.
Despite the drugs being initially used in heavily pretreated patients with advanced disease, anti-tumour effects are encouraging. Formestane has been associated with an objective response rate of 33% and remissions have been seen in patients previously treated with aminoglutethimide (Coombes, 1989) . This issue includes a report that fadrozole produces a 17% objective response rate in recurrent breast cancer after tamoxifen failure (Bonnefoi et al., 1996) Table I ).
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Future applications
The potent and specific characteristics of the new aromatase inhibitors suggest that they may have a wider utility than previous drugs. For example, it has always been puzzling as to why aromatase inhibitors should be effective after failure to antioestrogen if both types of drug have a common mechanism of oestrogen deprivation but the commonly expounded reasons for this are (i) antioestrogens such as tamoxifen are partial oestrogen agonists and may compete ineffectively for oestrogen receptors or (ii) under the selective pressure of antioestrogen treatment tumours become increasingly sensitive to oestrogen. In these circumstances aromatase inhibitors that reduce oestrogen levels may produce antitumour effects. If this is the case, more potent aromatase inhibitors that suppress oestrogen levels beyond those previously achievable, could increase cell kill and produce higher response rates.
A second area for exploitation is as an adjuvant to surgery in early stages of the disease. The acceptability of adjuvant therapy depends critically upon lack of side-effects. This is especially important for adjuvant endocrine therapy, which probably needs to be given over an extended time period for most beneficial effects. Because, in comparison with previous aromatase inhibitors, second-and third-generation drugs appear to lack toxicity, there is pressure for adjuvant use. However, this may be premature until results are available on long-term administration. The concern is that prolonged suppression of oestradiol to unassayable levels may have severe detrimental effects on bone and the vasculature.
More potent aromatase inhibitors may also be effective in situations in which aromatase activity is high or induced. For example aminoglutethimide is not effective in premenopausal women , presumably because it cannot inhibit the inherently high aromatase activity in the ovary or the reflex feedback loops that result in compensatory increases in enzyme and androgen substrate. More potent and specific inhibitors may be able to be given in sufficient doses to overcome these effects and suppress oestrogens to post-menopausal levels.
Theoretical and practical perspectives
There are theoretical reasons as to why specific aromatase inhibitors may not achieve complete oestrogenic blockade in vivo. Thus, whereas the drugs inhibit peripheral aromatase almost completely, levels of circulating oestrogens fall only by 40-85% (Masamura et al., 1994 Finally there is the practical consideration as to which of the new inhibitors will make the greatest clinical impact. At present, this is impossible to answer. Several inhibitors have similar profiles with regard to their potency, specificity, clinical efficacy and tolerability. It may come down to cost and marketing -a chastening thought given the vast scientific/clinical effort invested in developing and assessing the drugs.
